• Home
  • HCN Trends
  • Contact Us

Search Articles

Cardiology Covid-19 Dermatology Endocrinology General Interest Hematology Infectious Disease Neurology Oncology Pediatrics Psychiatry Pulmonology Rheumatology Surgery Uncategorized
acetaminophen actemra adverse events anemia antibody anxiety azithromycin bipolar disorder bleeding blog brain tumor breast cancer burnout Cancer capecitabine capmatinib cervical cancer chloroquine chronic pain clinical trials cloroquine CME compensation coronary artery disease coronavirus cost covid-19 death diagnosis doctors dosing drug interactions efficacy erlotinib exercise FDA/regulation fever filters glioblastoma green tea guidelines hemophilia hiv hospital hydroxychloroquine ibrutinib ibuprofen immunity induction chemotherapy infectious disease influenza ipilimumab irinotecan iron-deficiency anemia isn letrozole leukemia Lung cancer malaria mask Masks mbc MDS medical cannabis medical school Medicine mesothelioma metastatic colorectal cancer Myelodysplastic Syndromes myeloid leukemia nivolumab nsclc olaparib osimertinib outcomes pandemic patient safety patients pediatrics perjeta physicians podcast practice practice management prevention procedure prostate cancer radiation remdesivir research/studies respirators respiratory retevmo rucaparib sars SCLC selinexor selpercatinib sorafenib stroke Survival/Mortality symptoms syndrome telemedicine testing therapy thrombosis thyroid cancer time tnbc tocilizumab trastuzumab treatment vaccine venetoclax xpovio

Tag: erlotinib

Haymarket MediaLow-Dose Erlotinib an Option for Frail or Elderly Patients w. NSCLC?

According to the results of a single-arm, multicenter phase 2 trial in JAMA Oncology, low-dose erlotinib may be a safe and effective option for frail or elderly patients with EGFR mutation-positive NSCLC.

dosingerlotinibpatients
  • © Healthcare Communications Network
  • Privacy Policy